IRIS
TAGLIAFERRI, PIEROSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.307
AS - Asia 1.883
EU - Europa 1.782
SA - Sud America 28
Continente sconosciuto - Info sul continente non disponibili 24
AF - Africa 22
OC - Oceania 18
Totale 8.064
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.121
SG - Singapore 1.250
IT - Italia 948
CN - Cina 378
SE - Svezia 299
GB - Regno Unito 251
CA - Canada 171
IN - India 97
DE - Germania 69
NL - Olanda 42
HK - Hong Kong 28
FI - Finlandia 23
EU - Europa 22
JO - Giordania 22
RO - Romania 22
PK - Pakistan 21
RU - Federazione Russa 21
UA - Ucraina 19
FR - Francia 17
IR - Iran 15
AU - Australia 14
ID - Indonesia 13
ES - Italia 12
AT - Austria 11
SA - Arabia Saudita 11
BR - Brasile 10
CL - Cile 8
EE - Estonia 8
PT - Portogallo 8
CZ - Repubblica Ceca 7
EG - Egitto 7
LT - Lituania 7
MX - Messico 7
AE - Emirati Arabi Uniti 6
IE - Irlanda 6
JP - Giappone 6
ZA - Sudafrica 6
MY - Malesia 5
CU - Cuba 4
CY - Cipro 4
KR - Corea 4
NZ - Nuova Zelanda 4
TW - Taiwan 4
BG - Bulgaria 3
ET - Etiopia 3
LB - Libano 3
LK - Sri Lanka 3
MA - Marocco 3
NG - Nigeria 3
PE - Perù 3
PH - Filippine 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BD - Bangladesh 2
CH - Svizzera 2
CO - Colombia 2
EC - Ecuador 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
HU - Ungheria 2
IL - Israele 2
PS - Palestinian Territory 2
TR - Turchia 2
AR - Argentina 1
BE - Belgio 1
BO - Bolivia 1
GR - Grecia 1
IQ - Iraq 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
VN - Vietnam 1
Totale 8.064
Salva come PNG Salva come JPEG
Città #
Chandler 807
Santa Clara 376
Singapore 367
Milan 349
Lawrence 343
Princeton 343
Chicago 226
London 204
Wilmington 185
Ottawa 159
Ashburn 119
Des Moines 115
Catanzaro 105
Beijing 51
Shanghai 43
Boardman 40
Norwalk 33
Pune 33
Rome 32
Guangzhou 30
Redmond 27
Hong Kong 24
Helsinki 23
Los Angeles 21
Naples 21
Redwood City 21
Munich 19
Parma 16
San Nicola Manfredi 16
Shenzhen 16
Amman 14
Cosenza 12
Horia 12
Palermo 12
Spezzano della Sila 12
Hanover 11
Mountain View 11
Augusta 10
Reggio Calabria 10
West Jordan 10
Jiaxing 9
Seattle 9
Delhi 8
Ercolano 8
Irbid 8
Madrid 8
Santo Stefano di Rogliano 8
Council Bluffs 7
Kaunas 7
Leawood 7
New York 7
Rogliano 7
Settingiano 7
Washington 7
Afragola 6
Aversa 6
Catania 6
Melito di Porto Salvo 6
Nanjing 6
Timisoara 6
Toronto 6
Wuxi 6
Xi'an 6
Zhengzhou 6
Amsterdam 5
Andover 5
Cardiff 5
Frankfurt am Main 5
Islamabad 5
Lucknow 5
Meppel 5
Moscow 5
Olomouc 5
Riyadh 5
Sacramento 5
Sarno 5
Siano 5
Ahmedabad 4
Bari 4
Brescia 4
Cape Town 4
Clearwater 4
Decollatura 4
Hefei 4
Hyderabad 4
Jeddah 4
Lahore 4
Manchester 4
Melbourne 4
Nicosia 4
Oristano 4
Paris 4
San Antonio 4
San Mateo 4
Seaham 4
Soverato Marina 4
Taranto 4
Tehran 4
Acquaviva delle Fonti 3
Addis Ababa 3
Totale 4.600
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 309
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 73
miR-22 suppresses DNA ligase III addiction in multiple myeloma 73
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 60
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 58
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 53
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 52
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 51
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 51
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 49
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 47
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 47
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 46
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 46
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 45
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 44
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 43
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 41
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 41
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 40
CARDIOVASCULAR MONITORING OF DRUG-RESISTANT LYMPHOMA PATIENTS TREATED WITH EPOCH CHEMOTHERAPY PLUS HIGH-DOSE VERAPAMIL IN CONTINUOUS-INFUSION 40
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 39
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 39
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 38
Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration - Antitumor activity and immunomodulatory effects 38
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 38
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas 37
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 36
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 35
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 35
Mir-34: a new weapon against cancer? 35
Mir-221/222 are promising targets for innovative anticancer therapy 35
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents 35
A35 SINGLE NUCLEOTIDE POLYMORPHISMS OF THE ABCG1 AND ABCC5 TRANSPORTER GENES CORRELATE TO IRINOTECAN-ASSOCIATED GASTROINTESTINAL TOXICITY IN COLORECTAL CANCER PATIENTS AS ASSESSED BY DMET MICROARRAY PROFILING 35
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 35
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 35
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 34
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 34
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial 34
Mmrf-commpass data integration and analysis for identifying prognostic markers 34
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 34
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 33
COOPERATIVE ANTIPROLIFERATIVE EFFECTS OF 8-CHLORO-CYCLIC AMP AND 528 ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODY ON HUMAN CANCER-CELLS 33
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC) 33
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation 33
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 33
2 CLASSES OF CAMP ANALOGS SYNERGISTICALLY INHIBIT P21 RAS PROTEIN-SYNTHESIS AND PHENOTYPIC TRANSFORMATION OF NIH/3T3 CELLS TRANSFECTED WITH HA-MUSV DNA 32
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives 32
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 32
Second-line treatment of non-small cell lung cancer by biweekly gemcitabine and docetaxel plus /- granulocyte-macrophage colony stimulating factor and low dose aldesleukine 32
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 32
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 32
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 32
Proteomic profiling of inherited breast cancer: Identification of molecular targets for early detection, prognosis and treatment, and related bioinformatics tools 32
REVERSAL OF ADRIAMYCIN RESISTANCE BY RECOMBINANT ALPHA-INTERFERON IN MULTIDRUG-RESISTANT HUMAN COLON-CARCINOMA LOVO-DOXORUBICIN CELLS 31
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells 31
5-AZA-2'-DEOXYCYTIDINE INDUCES GROWTH-INHIBITION AND UP-REGULATION OF EPIDERMAL GROWTH-FACTOR RECEPTOR ON HUMAN EPITHELIAL CANCER-CELLS 31
miR-221/222 inhibitors for the treatment of multiple myeloma 31
DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine 31
Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: Preclinical and clinical implications 30
Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment 30
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of cancer 30
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 30
IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cells 30
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 30
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 30
Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: Experimental models and translational issues 29
EGF-R small inhibitors and anti-EGF-R antibodies: Advantages and limits of a new avenue in anticancer therapy 29
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 29
LOW-DOSE DOPAMINE INDUCES EARLY RECOVERY OF RECOMBINANT INTERLEUKIN-2 IMPAIRED RENAL-FUNCTION 29
SITE-SELECTIVE CAMP ANALOGS AT MICROMOLAR CONCENTRATIONS INDUCE GROWTH ARREST AND DIFFERENTIATION OF ACUTE PROMYELOCYTIC, CHRONIC MYELOCYTIC, AND ACUTE LYMPHOCYTIC HUMAN-LEUKEMIA CELL-LINES 29
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 29
Effects of transforming growth factor-β and budesonide on mitogen-activated protein kinase activation and apoptosis in airway epithelial cells 29
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 29
Integration of DNA Microarray with Clinical and Genomic Data 29
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 28
The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis. 28
Slow release lanreotide in combination with interferon-α2b in the treatment of symptomatic advanced medullary thyroid carcinoma 28
The farnesyltransferase inhibitor R115777 (ZARNESTRA®) enhances the pro-apoptotic activity of interferon-α through the inhibition of multiple survival pathways 28
8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal growth factor 28
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth 28
A PH-DEPENDENT DIFFERENTIAL CYTO-TOXICITY OF OUABAIN FOR HUMAN-CELLS TRANSFORMED BY CERTAIN ONCOGENES 28
miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling. 28
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma 28
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients 28
Proteomic pattern of BRCA1-deficient and reconstituted HCC1937 breast cancer cells: correlation with sensitivity profile to mitotic spindle poisoning drugs 28
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 28
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 28
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 28
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 27
PHORBOL 12-MYRISTATE 13-ACETATE (PMA) INDUCES NEUROENDOCRINE-LIKE DIFFERENTIATION AND REVERSES DOXORUBICIN-RESISTANCE OF HUMAN COLON-CARCINOMA CELLS IN-VITRO 27
Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI) 27
Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM) 27
C2673-8. CD10/common acute lymphoblastic leukemia-associated antigen and adhesion factor expression is predictive for lymphokine-activated killing sensitivity of adult B-lineage acute lymphoblastic leukemia 27
Differential sensitivity to non-major histocompatibility complex-restricted recombinant interleukin 2-activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or protein kinase A subunits 27
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it? 27
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 27
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 27
Immunotherapy of colorectal cancer: new perspectives after a long path 26
Transient exposure to cytarabine increases peptide growth factor receptor expression and tumorigenicity of melanoma cells 26
Totale 3.758
Salva come PNG Salva come JPEG
Categoria #
all - tutte 124.116
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 124.116
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020171 0 0 0 0 0 0 0 0 0 0 48 123
2020/2021387 63 4 10 18 45 31 33 16 48 69 44 6
2021/2022952 17 6 12 278 50 19 31 197 95 91 144 12
2022/20232.556 706 75 83 206 274 227 13 161 387 160 214 50
2023/20241.353 310 134 115 93 94 320 40 53 15 46 61 72
2024/20252.829 551 241 183 127 225 512 108 153 477 247 5 0
Totale 8.343